Boryung Pharmaceutical Appoints Jang Doo-hyun as New CEO... Transition to Sole CEO System
Jang Doo-hyun, the new CEO of Boryung Pharmaceutical (Photo by Boryung Pharmaceutical)
View original image[Asia Economy Reporter Kim Ji-hee] Boryung Pharmaceutical held a board meeting on the 30th and appointed Jang Doo-hyun, Executive Vice President of Management, as the new CEO.
At the board meeting, Boryung Pharmaceutical resolved to change the dual CEO system of Ahn Jae-hyun and Lee Sam-soo to a sole CEO system with Jang Doo-hyun as the sole CEO. Additionally, the promotion of Vice President Jang to President was also announced.
Regarding this CEO change, the company explained that it was a decision "to responsibly carry out the mid- to long-term management strategy and next year's management plan." Ahn Jae-hyun and Lee Sam-soo will continue their roles as inside directors and chairs of the top management committee.
Hot Picks Today
While Samsung Falters, China Rises: "Chinese DRAM" Turns a Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- "Striking Will Lead to Regret": Hyundai-Kia Employees Speak Out... Uneasy Stares Toward Samsung Union
- Despite Captivating the Nation for Over a Month... "Timmy" the Whale Ultimately Found Dead
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
Meanwhile, Boryung Pharmaceutical is promoting the LBA strategy as a growth engine to enhance management efficiency, strengthen global competitiveness, and adapt to the changing business environment after COVID-19. Last month, the company secured approximately 100 billion KRW in investment funds through a rights offering, making efforts to discover and secure mid- to long-term growth engines.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
